U.S. Supreme Court’s Prometheus Decision Further Defines the Scope of Patent Eligibility. What is the Impact on Personalized Medicine, Molecular Diagnostics and Human Gene Patents?-Teresa Corbin and Pauline Farmer-Koppenol -04/17/2012 - 8:30am

Event Information
Event Topic: 
U.S. Supreme Court’s Prometheus Decision Further Defines the Scope of Patent Eligibility. What is the Impact on Personalized Medicine, Molecular Diagnostics and Human Gene Patents?
Event Date: 
04/17/2012 - 8:30am
Event Location: 
Sunnyvale City Council Chambers, 456 West Olive Ave., Sunnyale, CA
Speaker Information
Event Speaker: 
Teresa Corbin and Pauline Farmer-Koppenol
Event Speaker Title: 
Partner, Intellectual Property & Litigation Groups and Associate, Intellectual Property Group respectively
Event Speaker Company: 
Fenwick & West
Event Speaker Bio: 

Terry Corbin, Partner, Fenwick & West

Pauline Farmer-Koppenol, Associate, Fenwick & West

Terry Corbin is a partner with Fenwick & West with extensive experience in strategic IP counseling and patent litigation for technology and life science companies. Ms. Corbin tries patent cases in federal district courts throughout the country and has successfully handled appeals to the Federal Circuit Court of Appeals and the U.S. Supreme Court.

Pauline Farmer-Koppenol's practice focuses on serving technology and life sciences clients in prosecuting patent applications, providing intellectual property strategy and counseling, and negotiating joint research agreements and patent licenses. Additionally, Ms. Farmer has analyzed patent portfolios for life science clients and investors.

Event Details
Cost: 
$0
Event Details: 

U.S. Supreme Court’s Prometheus Decision Further Defines the Scope of Patent Eligibility. What is the Impact on Personalized Medicine, Molecular Diagnostics and Human Gene Patents?

• In Mayo v. Prometheus, the Supreme Court struck down Prometheus’ patents, which included method claims for determining the adequate dosage of thiopurine drugs in the treatment of Chrohn’s and other autoimmune diseases, as an attempt to impermissibly patent a “law of nature.”

• Since the Prometheus decision, the Supreme Court has ordered the Federal Circuit to reconsider its decision upholding as valid Myriad Genetics’ patents covering isolated DNA sequences and methods for analyzing genetic mutations linked to increased risk of breast and ovarian cancer.

Teresa (Terry) Corbin and Pauline Farmer-Koppenol will discuss the Prometheus decision, its impact on the life sciences industry, and what can be done now to strengthen existing patents and pending claims.

Payment Options Dec 12th Evening Event

Attention B2DG members: You must login to your account first to see the members' early-bird admission rate.
If you are not a B2DG member or if you had missed the early-bird deadline, the registration fee is $20. Please follow these instructions to register.

We use PAYPAL to process your online payment. Print and bring a copy of your online receipt with you. If space permits, walk-ins are welcomed; please be prepared to pay $25 at the door (cash or check). There is no refund, exchange, or transfer. Thank you for your cooperation.
To register now, please select your meal preference from the pull-down menu below and enter the attendee's information. Then click on the "Pay Now" button to reach the PayPal payment page. Each attendee must be registered separately.
Make sure you enter the attendee's meal choice, name, and email address.


Meal Choice
Name of Attendee
Email Address